Symptoms and General Pathology

All Conditions

Neoplasms

Blood and Lymph Conditions

Immune System Diseases

Heart and Blood Diseases

Rare Diseases

Syndrome

Leukemia

Leukemia, Myeloid

Leukemia, Myeloid, Acute

Preleukemia

Myelodysplastic Syndromes

Lymphoma

Lymphoma, T-Cell

Lymphoma, T-Cell, Peripheral

Multiple Myeloma

Neoplasms, Plasma Cell

Hematologic Neoplasms

Neoplasms by Histologic Type

Lymphoproliferative Disorders

Lymphatic Diseases

Immunoproliferative Disorders

Hemostatic Disorders

Blood Coagulation Disorders

Vascular Diseases

Paraproteinemias

Blood Protein Disorders

Hematologic Diseases

Hemorrhagic Disorders

Lymphoma, Non-Hodgkin

Bone Marrow Diseases

Myeloid Leukemia

Acute Myeloid Leukemia

Acute Non Lymphoblastic Leukemia

Lymphosarcoma

Peripheral T-cell Lymphoma

Acute Graft Versus Host Disease

Anti-Inflammatory Agents

Antineoplastic Agents

Antiemetics

Gastrointestinal Agents

All Drugs and Chemicals

Dexamethasone

Venetoclax

Azacitidine

Pomalidomide

Dexamethasone acetate

Glucocorticoids

Hormones

Hormone Antagonists

Antineoplastic Agents, Hormonal

Antimetabolites

Enzyme Inhibitors

Immunologic Factors

Angiogenesis Inhibitors

Growth Inhibitors

CCS1477 monotherapy, CCS1477 combination with pomalidomide-dexamethasone

CCS1477 monotherapy, CCS1477 combination with azacitidine, CCS1477 combination with azacitidine and venetoclax

CCS1477

Tomasz Knurowski, PhD

Karen Clegg, MD, MFPM

Dima El-Sharkawi

Steven Knapper

Victoria Campbell

Mhairi Copland

Harriet Walter

Jenny O'Nions

Tim Somervaille

Paresh Vyas

Andy Davies

A Phase 1/2a study to assess the safety, tolerability, PK and biological activity of CCS1477 in patients with Non-Hodgkin Lymphoma, Multiple Myeloma, Acute Myeloid Leukaemia or High Risk Myelodysplastic syndrome.

This includes patients with Peripheral T-cell lymphoma.

The RP2D/MTD dose will be determined in Parts A and B. Parts C, D, E and F of the study may recruit patients concurrently.

Study to Evaluate CCS1477 in Haematological Malignancies

An Open-label Phase I/IIa Study to Evaluate the Safety and Efficacy of CCS1477 as Monotherapy and in Combination in Patients With Advanced Haematological Malignancies.

At this stage, is not currently planned that any IPD information will be shared with other researchers outside of the Sponsor and Clinical Research Organisations involved in the conduct of this study.

Treatment-related adverse events and serious adverse events

Laboratory abnormalities characterised by type, frequency, severity and timing

Defined as number of patients who have a response according to

* RECIL criteria (NHL)
* IMWG criteria (Multiple myeloma)
* ELN recommendations 2017 (AML)

Defined as the time from start of treatment until disease progression

Area under the plasma concentration-time curve (AUC) from time 0 to the time of the last measurable concentration of CCS1477

Maximum observed plasma concentration (Cmax) of CCS1477

CellCentric Ltd.

Skin and Connective Tissue Diseases

Respiratory Tract (Lung and Bronchial) Diseases

Urinary Tract, Sexual Organs, and Pregnancy Conditions

Breast Neoplasms

Carcinoma, Non-Small-Cell Lung

Prostatic Neoplasms

Neoplasm Metastasis

Lung Neoplasms

Carcinoma

Carcinoma, Bronchogenic

Bronchial Neoplasms

Respiratory Tract Neoplasms

Thoracic Neoplasms

Lung Diseases

Respiratory Tract Diseases

Pharmaceutical Solutions

Neuroprotective Agents

Atezolizumab

Abiraterone Acetate

Prednisone

Prednisolone

Olaparib

Methylprednisolone

Methylprednisolone Acetate

Methylprednisolone Hemisuccinate

Prednisolone acetate

Prednisolone hemisuccinate

Prednisolone phosphate

Immune Checkpoint Inhibitors

Antineoplastic Agents, Immunological

Poly(ADP-ribose) Polymerase Inhibitors

Cytochrome P-450 Enzyme Inhibitors

CCS1477 monotherapy in patients with mCRPC

CCS1477 plus abiraterone acetate in patients with mCRPC

CCS1477 plus enzalutamide in patients with mCRPC

CCS1477 expansion phase in patients with advanced solid tumours with molecular markers which may indicate potential for response to p300/CBP inhibition

CCS1477 plus darolutamide in patients with mCRPC

CCS1477 plus olaparib in patients with mCRPC or metastatic breast cancer.

CCS1477 plus atezolizumab in patients with non-small cell lung cancer

Abiraterone acetate 500mg tablets plus prednisone/prednisolone

Abiraterone acetate

Enzalutamide

Darolutamide

840mg/14ml concentrate for solution for infusion vials

Tomasz Knurowski, MD, MFPM

Karen Clegg, PhD

Victoria Coyle

Daniel Ford

Simon Pacey

Aravind Sundaramurthy

Richard Wilson

Louise Carter

Ruth Plummer

Simon Crabb

Johann de Bono

Johann de Bono, MD

A Phase 1/2a study to assess the safety, tolerability, PK and biological activity of CCS1477 in patients with metastatic castration resistant prostate cancer, metastatic breast cancer, non-small cell lung cancer or advanced solid tumours.

The RP2D/MTD dose will be determined in Part A. Parts B-H will run in parallel after the completion of Part A.

Study to Evaluate CCS1477 in Advanced Tumours

An Open-label Phase I/IIa Study to Evaluate the Safety and Efficacy of CCS1477 as Monotherapy and in Combination, in Patients With Advanced Solid/Metastatic Tumours.

Clinical chemistry and haematology assessments

PSA response as defined by Prostate Cancer Clinical Trial Working Group 3 (PCWG-3)

CTC response defined as a change from unfavourable (five or more cells) at baseline to favourable (four or fewer cells) post treatment

* malignant soft tissue response rate (Response Evaluation Criteria in Solid Tumours \[RECIST\] v1.1)
* metastatic bone disease status (PCWG-3 bone scan criteria)

Defined as the time from start of treatment until objective disease progression as defined by RECIST 1.1 or PCWG-3 or death

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
Study to Evaluate CCS1477 in Haematological Malignancies	NCT04068597	Haematological ... Acute Myeloid L... Non Hodgkin Lym... Multiple Myelom... Higher-risk Mye... Peripheral T Ce...	CCS1477 Pomalidomide Dexamethasone Azacitidine Venetoclax	18 Years -	CellCentric Ltd.
Study to Evaluate CCS1477 in Advanced Tumours	NCT03568656	Metastatic Cast... Metastatic Brea... Non-small Cell ... Advanced Solid ...	CCS1477 Abiraterone ace... Enzalutamide Darolutamide Olaparib Atezolizumab	18 Years -	CellCentric Ltd.

Spots Global Cancer Trial Database for ccs1477

Every month we try and update this database with for ccs1477 cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Spots Global Cancer Trial Database for ccs1477

Every month we try and update this database with for ccs1477 cancer trials from around the world to help patients and their families find trials that might be right for them. We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Every month we try and update this database with for ccs1477 cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.